Ravanex^® Ribavirin

Status: Clinical development complete.

Ribavirin is a chemically-derived synthetic nucleoside analogue of guanosine that has a broad spectrum anti-viral effect by inhibiting RNA polymerase of various RNA viruses.

Biopartners has developed a patented, coated tablet formulation of ribavirin, Ravanex^® , which is a tablet for daily use, solely in combination with interferon alpha for the treatment of chronic, active hepatitis C. 

Around 200 million people worldwide are infected with hepatitis C (about 3.3% of the world‘s population) and over 80% are chronically infected, with 3-4 million new infections each year.

* Datamonitor 2005